Evidence map›Paper›PMID 40667769›Full record

ArticleActa paediatrica (Oslo, Norway : 1992)2025

The Incidence of Type 1 Diabetes in Sweden During 2008-2021.

Yazan Al Abed, Araz Rawshani, Aidin Rawshani, Björn Eliasson, Mohammad Al Masri, Gustaf Lernfelt, Daniel Novak, Joanna Pestalozzi, Maria Henningsson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta paediatrica (Oslo, Norway : 1992), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yazan Al AbedDepartment of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID 0009-0006-0187-5433
Araz RawshaniDepartment of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Aidin RawshaniDepartment of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Björn EliassonDepartment of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0003-2569-4160
Mohammad Al MasriDepartment of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Gustaf LernfeltDepartment of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Daniel NovakDepartment of Pediatrics, Sahlgrenska University Hospital, Gothenburg, Region Västra Götaland, Sweden.
Joanna PestalozziDepartment of Pediatrics, Sahlgrenska University Hospital, Gothenburg, Region Västra Götaland, Sweden.
Maria HenningssonDepartment of Pediatrics, Sahlgrenska University Hospital, Gothenburg, Region Västra Götaland, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsWe analysed type 1 diabetes incidence in individuals aged 0-24 years from 2008 to 2021, with a focus on age at onset and potential changes during the COVID-19 pandemic.

methodsType 1 diabetes incidence was assessed using insulin prescriptions from the Prescribed Drug Register. One or more prescriptions defined a case in males; three or more were required in females. Data were stratified into 5-year age groups and analysed over the 2008-2021 period.

resultsType 1 diabetes incidence increased by 12% in individuals aged 0-24 years in 2021 compared to 2008-2019. The highest 2021 incidence was observed in the 0-4, 5-9 and 20-24 age groups. The 10-14 group consistently had the highest rates overall, followed by 5-9, 15-19, 20-24 and 0-4. Incidence was stable prepandemic, and a significant decline in age at onset was observed over time.

conclusionsA shift in the age of onset of type 1 diabetes towards younger ages was observed between 2008 and 2021. The increased incidence in 2021 could be influenced by a possible delayed effect of the widespread SARS-CoV-2 infections during the COVID-19 pandemic.

Indexed as

COVID-19Diabetes Mellitus, Type 1AdolescentAge of OnsetChildChild, PreschoolFemaleHumansIncidenceInfantInfant, NewbornMaleRegistriesSwedenYoung Adult

Identifiers

PMID40667769
PMCPMC12599597

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.